GNRH1 and benign muscle neoplasm: The mainstay of medical therapy, namely gonadotropin-releasing hormone (GnRH) agonist, reduces myoma size by 30–65% within 3 months of therapy; but this effect is limited, with a rapid return to pretreatment size occurring after therapy along with significant side effects related to the associated hypoestrogenism.